miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.